Related by context. All words. (Click for frequent words.) 79 Granulocyte Colony Stimulating Factor 79 Prolongs Survival 79 Drug Candidate 78 Receives Orphan Drug Designation 78 Antitumor 77 Files IND 77 Monoclonal Antibody 77 Systemic Delivery 77 Kinase Inhibitor 77 Hsp# Inhibitor 77 Investigational Compound 77 Anti Tumor 77 Aurora Kinase 77 Interferon Beta 77 Novel Oral 76 Receptor Agonist 76 Present Preclinical Data 76 Antithrombin 76 Presents Preclinical Data 76 Pegylated 76 Meets Primary Endpoint 76 Submits NDA 76 Single Dose 76 Initiate Clinical Trial 76 Phase 2b Clinical Trial 76 Synthetic Peptide 76 Factor Receptor 76 Initiates Clinical 75 Azacitidine 75 Patients Treated With 75 Signaling Pathway 75 Zorbtive TM 75 Inhibits 75 Completes Patient Enrollment 75 Platelet Derived Growth 75 Mg Usa 75 PEGylated anti 75 Severe Sepsis 75 Study Evaluating 75 Antitumor Activity 75 Phase 2a Trial 75 Phase 2a Clinical Trial 75 Mg Uk 75 Phase III Clinical Trial 75 IND Application 75 Novel Antibiotic 75 methylnaltrexone bromide 75 Demonstrates Significant 75 Fluticasone 75 Analogs 75 Phase 2b Trial 75 Attenuates 75 Long Term Efficacy 75 Pooled Analysis 75 Dendritic Cells 75 PRN FDA Approves 75 JAK Inhibitor 75 Parathyroid Hormone 74 Previously Treated 74 Epidermal Growth Factor Receptor 74 R Saizen R 74 Tumor Necrosis Factor 74 Investigational Agent 74 Bosutinib 74 Tezampanel 74 Orally administered 74 Clinical Trial Results 74 Transdermal Delivery 74 Sevelamer 74 Adjuvant Treatment 74 Orally Active 74 Chemokine Receptor 74 Phase IIb Clinical Trial 74 CYP#A# CYP#D# 74 Complicated Skin 74 Phase IIb Trial 74 Antigen Specific 74 Retinoic Acid 74 Oral Fingolimod 74 Beneficial Effects 74 Transdermal Patch 74 protein tyrosine phosphatase 1B 74 Diabetic Nephropathy 74 Improves Survival 74 Cannabinoid 74 FDA Approvals 74 Pafuramidine 74 vapreotide acetate 73 Shows Promise Against 73 Fibroblast Growth Factor 73 humanized monoclonal 73 Diabetic Neuropathy 73 Pivotal Phase III 73 inhibitor COX 73 TNF Tumor Necrosis Factor 73 Therapeutic Potential 73 Tyrosine Kinase Inhibitor 73 Receives Approvable Letter 73 Dapagliflozin 73 Combination Therapy 73 Presents Preclinical 73 Fluconazole 73 Personalized Immunotherapy 73 Protease Inhibitor 73 NDA Submission 73 Novel Mechanism 73 Oral Insulin 73 Shows Promising 73 Reductase 73 Tumor Targeting 73 Prodrug 73 Initiate Phase 73 Replacement Therapy 73 Preclinical Data 73 Granted Orphan Drug 73 Small Molecule 73 FDA Okays 73 Bazedoxifene 73 Decitabine 73 Low Dose 73 FDA Accepts 73 Immunotherapeutic 73 Hepatitis B Vaccine 73 Ganciclovir 73 Receptor Antagonist 73 Antifungal 73 Romiplostim 73 Allogeneic 73 Oral Formulation 73 Anticancer Activity 73 Hepatocytes 73 Modulates 73 Fludara ® 73 Presents Positive 73 First Patient Dosed 73 Incretin 73 itraconazole Sporanox 73 dihydrochloride 73 Hypercholesterolemia 73 cromolyn sodium 73 Nucleoside 73 See CLINICAL PHARMACOLOGY 73 Successfully Completes Phase 73 Sustained Release 73 Well Tolerated 73 Phase IIa Clinical Trial 73 Teva Provides Update 73 Aptamer 73 Inhalation Aerosol 73 Maleate 72 CYT# potent vascular disrupting 72 Monoclonal 72 interleukin IL -# 72 Interferon Alpha 72 Itraconazole 72 Angiotensin Converting Enzyme 72 Calcium Acetate 72 Conjugated 72 cyclooxygenase COX 72 Glucagon Like Peptide 72 Demonstrated Significant 72 Initiates Enrollment 72 Technosphere ® 72 Receptor Antagonists 72 Completes Enrollment 72 Therapeutic Efficacy 72 Dehydrogenase 72 Rheumatoid Arthritis Drug 72 Trial Evaluating 72 Angiogenic 72 Mimetics 72 Liposomal 72 Intravenous Human 72 PEGylated Fab fragment 72 oral prodrug 72 Vaccine Adjuvant 72 Initiates Clinical Trial 72 Safinamide 72 Pivotal Phase 72 Investigational Treatment 72 SPRYCEL ® 72 Initiates Phase II 72 Generic Version 72 Rotavirus Vaccine 72 TO AVOID PREGNANCY WHILE 72 Fibrinogen 72 Glatiramer Acetate 72 Preclinical Study 72 FDA Clears 72 Adjunctive Therapy 72 Chronic Hepatitis C 72 Files Investigational 72 octreotide acetate 72 Immunomodulatory 72 Cholesterol Lowering Drug 72 Demonstrates Potential 72 Mylan Receives Approval 72 Lyophilized 72 Skeletal Muscle 72 Advanced Renal Cell 72 AnaSpec Introduces 72 Glucocorticoid 72 Histone Deacetylase 72 Secondary Hyperparathyroidism 72 Cytotoxic 72 Maribavir 72 AAG geldanamycin analog 72 Angiotensin 72 Posaconazole 72 Benign Prostatic Hyperplasia 72 Controlled Trial 72 Progenitor Cells 72 beta 1a 72 Anti Tumor Activity 72 Fondaparinux 72 Medoxomil 72 Plaque Psoriasis 72 topoisomerase II inhibitor 72 Psoriasis Drug 72 Upregulation 72 Therapeutic Vaccine 72 Generic Versions 72 thalidomide Thalomid 72 Ranolazine 72 Phospholipase A2 72 Refractory Hodgkin Lymphoma 72 Inhalation Solution 72 hyaluronidase enzyme 72 Relapsed Refractory 72 Cytochrome P# 72 Endothelial Cells 72 Chronic Hepatitis B 72 Lanthanum Carbonate 72 Smooth Muscle 72 Disease IBD 72 Double Blind Randomized 72 Is Well Tolerated 72 Receives Positive Opinion 72 Induces 72 ADP receptor antagonist 72 Anticancer Agent 72 Bone Morphogenetic Protein 72 5 HT2A serotonin 72 Announces Tentative Approval 72 Adenoviral 72 Demonstrates Positive 72 Mouse Model 72 Induces Apoptosis 72 Methylnaltrexone 72 Mycophenolate Mofetil 72 brand ciclesonide HFA 72 Tesamorelin 72 Anti Inflammatory 72 Tigecycline 71 MOVIPREP R 71 Anti Inflammatory Drug 71 2A receptor agonist 71 Fast Track Status 71 Hormone Refractory Prostate Cancer 71 C1 Inhibitor 71 Randomized Phase 71 Crit Rev 71 Plasmid DNA 71 Pramlintide 71 Vaginal Gel 71 Anticancer Drug 71 Pharmacokinetic Study 71 Recombinant Protein 71 Conjugate 71 ACE Inhibitors 71 Demonstrates Efficacy 71 HDAC Inhibitor 71 Pivotal Study 71 Indomethacin 71 Vildagliptin 71 Fulvestrant 71 small molecule thrombopoietin 71 hypereosinophilic syndrome 71 Unfractionated Heparin 71 Sulfonylurea 71 Initiates Phase III 71 Tacrolimus 71 Secretase 71 cetuximab Erbitux R 71 Patent Covering 71 receptor modulators 71 Lymphoid 71 Immune Responses 71 2 methoxyestradiol 71 sodium glucose cotransporter 71 Aganocide 71 Kuvan sapropterin dihydrochloride 71 selective modulator 71 Topical Cream 71 Initiates Clinical Trials 71 Budesonide 71 Novel Inhibitor 71 ergot derivatives 71 Lispro 71 mesylate 71 acetonide FA 71 Hematopoietic 71 calcitonin gene related 71 Treatment Naïve 71 Soft Tissue Sarcoma 71 Advanced Melanoma 71 Drug Shows Promise 71 Cutaneous T 71 pan HDAC inhibitor 71 Investigational Oral 71 Kepivance 71 Hypertensive Patients 71 Proteasome 71 Fluorouracil 71 Metastatic Melanoma 71 Efficacious 71 RNAi Therapeutic 71 novel VDA molecule 71 Xcytrin R 71 Combination REOLYSIN R 71 Androgen Receptor 71 docetaxel Taxotere ® 71 Dose Ranging Study 71 Peginterferon alfa 2b 71 Combination Treatment 71 Renal Cell Carcinoma 71 Am J Clin 71 Lung Cancer Drug 71 Formoterol 71 Haemophilus b Conjugate 71 Receives Milestone Payment 71 Vitro Activity 71 Cyclooxygenase 2 71 soluble tumor necrosis 71 Vidaza azacitidine 71 Demonstrates Potent 71 Novel Therapeutic 71 Interferon alfa 71 Peginterferon Alfa 2a 71 FDA APPROVES 71 Levaquin levofloxacin 71 Genotyping Test 71 Protein Kinase 71 sapropterin dihydrochloride 71 Patients Receiving 71 diclofenac Voltaren 71 Expanded Indication 71 Ovitrelle R Serostim 71 Diabetic Patients 71 norfloxacin 71 Tiotropium 71 Fungal Infections 71 Treating Chronic 71 Pharmacokinetics PK 71 Ondansetron Injection USP 71 Rheumatoid Arthritis Patients 71 Thrombin 71 IMiDs ® 71 Leukine ® 71 Levoleucovorin 71 Suppresses 71 ALN HPN 71 Improves Outcomes 71 Dasatinib 71 II Clinical Trial 71 RECOTHROM R 71 abacavir sulfate lamivudine 71 Allergic Rhinitis 71 Somatostatin 71 Sumatriptan Succinate 71 Phase III Trial 71 Humanized Anti 71 Inflammatory Diseases 71 cMET 71 Interferon Gamma 71 Levels Linked 71 Demonstrates Statistically Significant 71 Relapsing Multiple Sclerosis 71 Wafer polifeprosan 71 Initiates Phase 71 estrogen receptor antagonist 71 Oligonucleotides 71 Epoetin 70 Epoetin Alfa 70 Irinotecan 70 Elvitegravir 70 Biosimilar 70 somatostatin 70 Atopic Dermatitis 70 downregulates 70 pralatrexate injection folate analogue 70 diarrhea predominant irritable 70 Data Suggest 70 Improve Survival 70 Lubiprostone 70 Qutenza TM 70 Antigens 70 Newly Diagnosed Multiple Myeloma 70 bFGF 70 Belerofon 70 Statistically Significant 70 Polymorphisms 70 Interferon gamma 70 benzoic acid hyoscyamine sulfate 70 Thiazolidinediones 70 Preclinical Models 70 Myelodysplastic Syndromes 70 Hepatitis C Genotype 70 Nitazoxanide 70 prostanoid 70 Dose Finding 70 Capecitabine 70 pathophysiological effects 70 Copegus ® 70 uricase 70 chimeric monoclonal antibody 70 Macrophage 70 Novel Compound 70 Vicriviroc 70 FOLOTYN ® 70 Aztreonam Lysine 70 Monotherapy 70 STELARA TM 70 Glufosfamide 70 Achieves Primary Endpoint 70 Gonal f R 70 MetroGel 70 Fixed Dose 70 Develop Novel 70 Inhaled Corticosteroids 70 Interferons 70 Autologous Stem Cell Transplantation 70 Receives Orphan Drug 70 Shows Statistically Significant 70 IgG1 70 Breast Cancer Cells 70 Wound Dressing 70 Clinical Outcome 70 Prostate Cancer Vaccine 70 Sapacitabine 70 orally administered inhibitor 70 Novel Anti Inflammatory 70 Immune Globulin Human 70 Atypical Antipsychotic 70 Estrogen Receptor 70 Bendamustine 70 Lowers Risk 70 Saizen R 70 Shows Efficacy 70 fumarate 70 Vidaza R 70 Neuroprotection 70 HCV Protease Inhibitor 70 Calcitonin 70 Antiviral Activity 70 Cytotoxic T 70 rHuPH# recombinant human 70 Osteoporosis Treatment 70 Myelodysplastic Syndrome MDS 70 Moxifloxacin 70 Liprotamase 70 Begins Dosing 70 Confirmatory Phase 70 Protein Expression 70 Advanced Colorectal Cancer 70 Hydrochlorothiazide Tablets 70 Ziprasidone 70 Effectively Treats 70 platform HDL Mimetic 70 Protease Inhibitors 70 sorafenib tablets 70 Cyclosporin 70 Immunomedics Announces 70 Seasonal Influenza Vaccine 70 Significantly Improved 70 Receives Marketing Authorization 70 Tocopherol 70 telomerase therapeutic 70 Oral Spray 70 Reports Preclinical Data 70 HuMax 70 Dalbavancin 70 Protelos R 70 Inflammatory Arthritis 70 5alpha reductase 70 Drug Resistant 70 Pivotal Trial 70 Mouse Models 70 selective phosphodiesterase 70 Piperacillin 70 P#Y# [001] 70 Nicotine Vaccine 70 Hepatocellular Carcinoma 70 Immunosuppressant 70 Mesalamine 70 Antiplatelet 70 Pulmonary Arterial Hypertension 70 Patient Enrollment 70 dasatinib Sprycel ® 70 5 HT6 receptor 70 lutropin alfa 70 topically administered 70 Interferon alpha 70 TRANSDUR ™ 70 Survival Benefit 70 Janus Kinase 70 Vascular Inflammation 70 Brain Metastases 70 Tumor Growth 70 alpha GAL 70 Autoantibodies 70 Inflammatory Markers 70 Dendritic Cell 70 R lenalidomide 70 Soy Isoflavones 70 Neuroprotective Effects 70 Miconazole 70 Anticancer Compound 70 Oral Calcitonin 70 Janus kinase 70 5 Fluorouracil 70 vinorelbine tartrate 70 Epratuzumab 70 Gamunex C 70 peptidic compound 70 Protein Kinase C 70 CYP#A# substrate 70 ABLYNX 70 Transfection 70 prasterone 70 Therapeutic Competitors Companies 70 Tubulin 69 R bendamustine hydrochloride 69 Clinical Trial Evaluating 69 Ecallantide 69 Ascorbic Acid 69 Overactive Bladder 69 BAL# [002] 69 Glycosylation 69 Leukemias 69 Interferon Alfa 69 Postmenopausal Osteoporosis 69 Randomized Double Blind 69 terfenadine 69 Oligonucleotide 69 Adjuvant Chemotherapy 69 Peginterferon 69 Randomized Double blind 69 Phase III Trials 69 Esomeprazole 69 Lopinavir 69 Placebo Controlled Trial 69 Monopril 69 potently inhibit 69 Plus Ribavirin 69 Xeloda ® 69 Prilosec omeprazole 69 Bicalutamide 69 EGFR HER2 69 Sitagliptin 69 Oncolytic 69 Nilotinib 69 pioglitazone HCl 69 Monocytes 69 Monoclonal Antibodies 69 dihydrofolate reductase 69 HCl Tablets 69 Phosphorylation 69 Tofranil 69 Microspheres 69 Appears Safe 69 histone deacetylase inhibitor 69 hypoxia inducible factor 69 Lupus Drug 69 Olmesartan 69 inhibitor PPI 69 Fibroblast 69 Investigational Drug 69 Gout Drug 69 Darinaparsin 69 GTC recombinant human 69 Raptiva R 69 Nebulized 69 Polyethylene Glycol 69 lexidronam injection 69 Pruvel TM 69 interferon gamma 1b 69 Lowers Blood Pressure 69 TRANSDUR ® 69 Melphalan 69 DNA methyltransferase inhibitors 69 Cardiotoxicity 69 receptor blocker 69 Ciclesonide 69 Panzem R 69 Cancer Vaccines 69 Aflibercept 69 Disease Modifying 69 Metabolites 69 Protease 69 Antisense Oligonucleotides 69 mertansine 69 Submits IND 69 Regenerative Cells 69 phosphatidylinositol 3 69 Nat Clin Pract 69 Drug Fails 69 beta. 69 Inhibitory 69 Aviptadil 69 Interferon beta 69 Predict Response 69 Treatment Experienced 69 kallikrein 69 Galantamine 69 Previously Untreated 69 Diabetic Foot Ulcer 69 Paraplatin ® 69 Growth Hormone Deficiency 69 Phase III Clinical Trials 69 TNF Blockers 69 Biosynthetic 69 Aliskiren 69 KL4 Surfactant 69 Kidney Function 69 mGluR5 negative 69 SinuNase TM 69 anti CD3 69 Febuxostat 69 Gastrointestinal Stromal Tumors 69 Antiviral Drugs 69 Histone 69 Mucosal 69 Gastric Cancer 69 ceftazidime 69 gets USFDA nod 69 Immunogenicity 69 Myeloid 69 Blood Pressure Drug 69 Vaccine Adjuvants 69 Respiratory Virus 69 ALVESCO ® 69 Phase III Pivotal 69 Axid 69 FS Antihemophilic Factor Recombinant 69 dihydrochloride Tablets 69 Innate Immune 69 rabeprazole 69 chronic eosinophilic leukemia 69 monocyte chemotactic protein 69 Luteinizing Hormone Releasing Hormone 69 VISICOL R 69 Natalizumab 69 Mutational 69 Topical Suspension 69 Aldara ® 69 Long acting beta2 69 Therapeutic Competitors Report 69 Synthase 69 Preclinical Efficacy 69 Catenin 69 5 HT2A inverse 69 Superoxide 69 Treatment Reduces 69 urate oxidase 69 Oral Mucositis 69 Gets FDA Clearance 69 Positive Opinion 69 liposomal formulation 69 ARRY # 69 Oncogenic 69 Factor VIIa 69 Assay Kits 69 Antiangiogenic 69 Erythropoietin 69 Atripla combines 69 aripiprazole Abilify 69 selective adenosine 69 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 69 Phase 2b Study 69 N methyl 69 Pathway Inhibitor 69 JAK2 Inhibitor 69 Remicade infliximab 69 Lupus Nephritis 69 Sandimmune 69 Amino Acid 69 % Caprylate Chromatography 69 Hydrochloride Injection 69 Submits Biologics License Application 69 Kamada AAT 69 Ixabepilone 69 Meta Analysis 69 Arthritis Drug 69 METOZOLV TM ODT metoclopramide 69 HCl Injection 69 Prospective Randomized 69 Peginterferon alfa 2a 69 Trastuzumab Herceptin 69 Kinase Inhibitors 69 Interferon beta 1b 69 polyglutamate 69 Node Positive 69 Saizen ® 69 cortisol synthesis 69 Ketorolac 69 Uric Acid 69 Epithelial 69 Selective Inhibitor 69 targeted radiotherapeutic 69 Inhaled Insulin 69 Dose Escalation Study 69 Cholesterol Lowering 69 Chemotherapeutic Agents 69 ara C 69 Nicotinic 69 J Am Coll 69 Anthracycline 69 Zileuton 69 Vfend 69 Antigenics QS 69 investigational humanized monoclonal antibody 69 Epithelial Cell 69 HIF 1a 69 Fluticasone Propionate 69 HuCAL PLATINUM ® CysDisplay 69 Nanoemulsion 69 Fracture Risk 69 Hepatocellular 69 Serostim ® 69 Cancer Cells 69 COPEGUS R 69 indinavir Crixivan 69 Antidepressant Drug 69 Biosynthesis 69 Dose Response 69 HER1 69 Beta Blocker 69 Osteoporosis Drug 69 Emollient Foam 69 Topical Gel 69 pioglitazone hydrochloride 69 Anidulafungin 69 Levofloxacin 69 Chronic Constipation 69 Announces Poster Presentations 69 salmon calcitonin 69 Macrolide 69 Insulin Resistance 69 Isavuconazole 69 myelofibrosis polycythemia vera 69 Hydrochlorothiazide 69 Extended Release 69 Prophylactic Treatment 69 REPRONEX R menotropins 69 Glycine 69 Phosphodiesterase 69 Double Blind Placebo 69 YONDELIS 69 Hepatitis C Virus 69 SinuNase ™ 69 Protein Synthesis 69 Thyroid Hormone 69 RNAi Therapeutics 69 doxercalciferol 69 Commences Phase 69 Chronic Lymphocytic Leukemia 69 rxRNA 69 Metformin HCl 69 DNA intercalator 69 Fingolimod 69 Cell Transplants 69 Hyaluronan 69 Danazol 69 subcutaneous immunoglobulin 69 Lamotrigine 69 bevacizumab Avastin R 69 R bisoprolol Euthyrox 69 Alkeran 69 selective A2A adenosine receptor 69 Civacir 68 Randomized Clinical Trial 68 GHRH 68 Infected Patients 68 MKC# MT 68 include Phenoptin TM 68 tazobactam 68 Angiotensin II 68 Interferon beta 1a 68 prescribed proton pump 68 Topical Treatment 68 gastrointestinal stromal tumors GIST 68 pegylated 68 Gonal f ® 68 Cell Proliferation 68 intranasal formulation 68 Peripheral Blood 68 novel synthetic peptide 68 Desmopressin 68 Signaling Pathways 68 Bortezomib 68 Bioavailability 68 Intranasal 68 Subunit 68 palmitoyl 68 Azathioprine 68 Cyclooxygenase 68 Commence Phase 68 Lenalidomide 68 oral dual endothelin 68 epoetin delta 68 Camptosar ® 68 Tyrosine 68 Degarelix 68 novel emulsion formulation 68 nucleoside analog 68 iobenguane 68 Androgen 68 mTOR mammalian target 68 AMMONUL R sodium phenylacetate 68 OMNARIS 68 Treated Patients 68 Transcription Factor 68 Benazepril 68 etanercept Enbrel 68 Faropenem 68 Botulinum Toxin 68 immunostimulatory 68 Submits Supplemental 68 losartan potassium 68 Pravachol pravastatin 68 HCV RNA polymerase 68 #mg/#mg 68 pan histone deacetylase 68 DGAT 68 Hematological Malignancies 68 Myolimus 68 tenofovir Viread 68 Submits Response 68 BioSante Pharmaceuticals Announces 68 cyclin dependent kinase inhibitor 68 Immunogenic 68 BARACLUDE R 68 colony stimulating factor 68 RhuDex 68 Thiovir 68 Hepatitis B Virus 68 carcinoids originate 68 Antiviral Therapy 68 Tipranavir 68 ALVESCO R 68 non nucleoside inhibitor 68 fosbretabulin 68 Naive Patients 68 PROSTASCINT R 68 Launches Generic Version 68 Kahalalide F 68 PEGylated 68 lamotrigine Lamictal 68 selective immunoproteasome inhibitor 68 Adenosine A2A 68 N acetylgalactosamine 68 PKC# 68 non porcine pancreatic 68 orally inhaled 68 Metastatic Renal Cell Carcinoma 68 deoxy 68 Valsartan 68 anionic backbone 68 Pegloticase 68 Vaprisol 68 Insulin Glargine 68 Plasmin 68 Analgesic 68 Progenitor Cell 68 Randomized Double Blind Placebo 68 serine threonine 68 Novel Protein 68 Doripenem 68 Vitrasert R 68 Novel Small Molecule 68 topical gel formulation 68 Poster Presentations 68 Anti CD# Antibody 68 Anemia Drug 68 Myeloma Patients 68 diphosphate 68 myelodysplastic myeloproliferative diseases 68 avidin 68 LAB CGRP 68 sunitinib Sutent 68 Gene Variants 68 Alkaline Phosphatase 68 potent suppressor 68 Enzyme Replacement Therapy 68 peptide CGRP 68 Captopril 68 Pertuzumab 68 Vinorelbine 68 ritonavir boosted 68 microtubule inhibitor 68 Cathepsin S 68 Proves Effective 68 PDE4 68 Cholesterol Drug 68 Successfully Treated 68 Gliadel R 68 Pharmacodynamics 68 Develops Novel 68 Prostacyclin 68 Antipsychotic 68 cutaneous T 68 Patients Suffering 68 Metastatic Prostate Cancer 68 ketoconazole USP Gel 68 Cholinesterase Inhibitors 68 Bone Metastases 68 Squalamine 68 Multipotent 68 Kuvan R 68 Cytarabine 68 Announces FDA Clearance 68 Clindamycin 68 Hematopoietic Stem Cells 68 Rhinocort 68 Alfacell proprietary ribonuclease 68 Fixed Dose Combination 68 Epilepsy Drug 68 Boceprevir 68 IMiDs ® compound 68 Extracellular Matrix 68 inflammatory PDE 68 Non Responders 68 extensively metabolized 68 maleate 68 selective antagonist 68 follitropin alfa 68 INSPIRE Trial Phase III 68 rivastigmine Exelon 68 substrates inhibitors 68 Pemetrexed 68 Overexpression 68 Chitin 68 betamethasone dipropionate 68 Hypoxia Inducible Factor 68 inhalation aerosol 68 luteinizing hormone releasing 68 Pegylated Liposomal Doxorubicin 68 J Allergy Clin 68 Therapeutic Antibody 68 Factor VEGF 68 Neulasta ® 68 GRAS Status 68 selectively binds 68 Presents Positive Preclinical 68 targeted antifolate 68 Chromium Picolinate 68 oncolytic virus therapies 68 Disease Progression 68 l lysine 68 Randomized Phase II 68 Apoptotic 68 sodium benzoate prescription 68 Potent Inhibitor 68 paroxetine sertraline 68 Octreotide 68 Clinical Study Shows 68 TELINTRA 68 Taclonex R 68 aurora kinase 68 Clinical Efficacy 68 Luveris R Ovidrel R 68 Albuferon TM 68 Desvenlafaxine Succinate 68 Breast Cancer Metastasis 68 Potent Antiviral Activity 68 Patients Treated 68 Copegus ribavirin 68 Polymerase Inhibitor 68 Asthma COPD 68 alfa 2b 68 Serostim R 68 Cyclosporine 68 Salmeterol 68 Sangamo BioSciences Announces 68 ODT metoclopramide HCl PEPCID 68 metastatic malignant 68 Initiates Dosing 68 LibiGel ® 68 HER2 Positive 68 Advanced Prostate Cancer 68 interferon beta 1a infertility 68 Proteases 68 induced macular edema 68 Losartan 68 HMG CoA reductase inhibitors 68 selectively inhibited 68 TÎ ² 4 68 poly ADP ribose polymerase